| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 51.48 | -0.99 (-1.89%) | 41.68 - 54.00 | 1.9 million (Below Avg) |
Market data as of 4:01PM 06/19/13. Quotes are delayed by at least 15 min.
Research Study Results Bring Hope for Combating Debilitating Diseases - Research Report on Johnson & Johnson, AbbVie, Lilly, Novartis and GlaxoSmithKline
06/12/2013 8:00 AM ET
Renaissance and GlaxoSmithKline Agree to a Transfer of Nine Products
06/03/2013 12:04 PM ET
Two new GSK oral oncology treatments, BRAF-inhibitor Tafinlar® (dabrafenib) capsules and the first MEK-inhibitor Mekinist™ (trametinib) tablets, approved by FDA as single-agent therapies
05/29/2013 5:24 PM ET